Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Mortality Vs. Clinical Cure: Telavancin Review Expected To Renew Debate On Nosocomial Pneumonia Endpoints

Nov 27 2012

• By Sue Sutter

Related Content

Theravance Gets To Market With Vibativ, But HAP Indication Could Be Pushed To 2010

Sep 14 2009

Pneumonia Guidances Revisited: FDA Cmte. To Weigh Study Design Issues Again

Oct 03 2011

Panel Gives Mixed Reviews To Using Single Trial For Community-Acquired Pneumonia

Nov 14 2011

Theravance’s Vibativ To Get FDA Panel Review For Hospital-Acquired Pneumonia

Sep 19 2012

Hospital-Acquired Pneumonia Is Life Or Death, FDA Says; Recommends Sole Primary Endpoint

Dec 07 2010

Related Companies

Innoviva, Inc.

Pfizer Inc.

Astellas Pharma, Inc.

Hospira, Inc.

Additional Topics

United States Advisory Committees BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window